Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

Regarding the PDD data, the devil is in the details. Until we have the actual results we shouldn't assume too much.

As a knowledgeable poster opined on July 19:

"The point is simple. The battle is not only against significance (p <0.05) but also against historical deltas observed at a similar time (14 weeks and 16 weeks close enough). Knowing the historical expectation allows one to very quickly judge the top-line PR. If Anavex at either dose performs 5.5 or more points better than placebo then analysts will be more likely to consider the study a positive as it compared favorably to the only approved drug for PDD. If delta is 4 points or less, analysts will conclude the drug flopped. Secondary endpoint success (i.e. sleep like SYN120 showed) will not save the SP if the drug failed the primary endpoint. There can be a middle ground if the pre-defined genetic markers give a better delta than the entire cohort (this is a secondary endpoint), but Wall Street judges harshly and success or failure based on the primary endpoint."

Like I said, we need the actual data in order to judge the outcome. Until we get the data, investors will not be able to judge the result and will not bid the stock significantly higher.